메뉴 건너뛰기




Volumn 22, Issue , 2016, Pages S47-S51

Optimizing diagnosis in Parkinson's disease: Radionuclide imaging

Author keywords

5 hydroxytryptamine; Dopamine; Neuroinflammation; Positron emission tomography; Single photon emission computed tomography; Tau; synuclein

Indexed keywords

ACETYLCHOLINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE TRANSPORTER; NORADRENALIN; SEROTONIN; VESICULAR MONOAMINE TRANSPORTER 2; DOPAMINE; DOPAMINE RECEPTOR; RADIOISOTOPE;

EID: 84947865804     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.09.029     Document Type: Article
Times cited : (26)

References (30)
  • 1
    • 84894738679 scopus 로고    scopus 로고
    • In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET
    • Lin S.C., Lin K.J., Hsiao I.T., Hsieh C.J., Lin W.Y., Lu C.S., et al. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET. J. Nucl. Med. 2014, 55(1):73-79.
    • (2014) J. Nucl. Med. , vol.55 , Issue.1 , pp. 73-79
    • Lin, S.C.1    Lin, K.J.2    Hsiao, I.T.3    Hsieh, C.J.4    Lin, W.Y.5    Lu, C.S.6
  • 3
    • 18844471416 scopus 로고    scopus 로고
    • In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
    • Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 47(4):493-503.
    • (2000) Ann. Neurol. , vol.47 , Issue.4 , pp. 493-503
    • Lee, C.S.1    Samii, A.2    Sossi, V.3    Ruth, T.J.4    Schulzer, M.5    Holden, J.E.6
  • 4
    • 33646078787 scopus 로고    scopus 로고
    • Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography
    • Ginovart N., Galineau L., Willeit M., Mizrahi R., Bloomfield P.M., Seeman P., et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J. Neurochem. 2006, 97(4):1089-1103.
    • (2006) J. Neurochem. , vol.97 , Issue.4 , pp. 1089-1103
    • Ginovart, N.1    Galineau, L.2    Willeit, M.3    Mizrahi, R.4    Bloomfield, P.M.5    Seeman, P.6
  • 5
    • 81055144433 scopus 로고    scopus 로고
    • Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease
    • Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., McKenzie J., et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011, 134(Pt 11):3290-3298.
    • (2011) Brain , vol.134 , pp. 3290-3298
    • Nandhagopal, R.1    Kuramoto, L.2    Schulzer, M.3    Mak, E.4    Cragg, J.5    McKenzie, J.6
  • 6
    • 20444477480 scopus 로고    scopus 로고
    • Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system
    • Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128(Pt 6):1314-1322.
    • (2005) Brain , vol.128 , pp. 1314-1322
    • Remy, P.1    Doder, M.2    Lees, A.3    Turjanski, N.4    Brooks, D.5
  • 7
    • 77955844658 scopus 로고    scopus 로고
    • Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study
    • Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40(1):216-221.
    • (2010) Neurobiol. Dis. , vol.40 , Issue.1 , pp. 216-221
    • Politis, M.1    Wu, K.2    Loane, C.3    Kiferle, L.4    Molloy, S.5    Brooks, D.J.6
  • 8
    • 0347385143 scopus 로고    scopus 로고
    • Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study
    • Bohnen N.I., Kaufer D.I., Ivanco L.S., Lopresti B., Koeppe R.A., Davis J.G., et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. 2003, 60(12):1745-1748.
    • (2003) Arch. Neurol. , vol.60 , Issue.12 , pp. 1745-1748
    • Bohnen, N.I.1    Kaufer, D.I.2    Ivanco, L.S.3    Lopresti, B.4    Koeppe, R.A.5    Davis, J.G.6
  • 9
    • 73449090105 scopus 로고    scopus 로고
    • History of falls in Parkinson disease is associated with reduced cholinergic activity
    • Bohnen N.I., Muller M.L., Koeppe R.A., Studenski S.A., Kilbourn M.A., Frey K.A., et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73(20):1670-1676.
    • (2009) Neurology , vol.73 , Issue.20 , pp. 1670-1676
    • Bohnen, N.I.1    Muller, M.L.2    Koeppe, R.A.3    Studenski, S.A.4    Kilbourn, M.A.5    Frey, K.A.6
  • 10
    • 77952998970 scopus 로고    scopus 로고
    • Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease
    • Bohnen N.I., Muller M.L., Kotagal V., Koeppe R.A., Kilbourn M.A., Albin R.L., et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010, 133(Pt 6):1747-1754.
    • (2010) Brain , vol.133 , pp. 1747-1754
    • Bohnen, N.I.1    Muller, M.L.2    Kotagal, V.3    Koeppe, R.A.4    Kilbourn, M.A.5    Albin, R.L.6
  • 11
    • 84860122434 scopus 로고    scopus 로고
    • Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease
    • Kotagal V., Albin R.L., Muller M.L., Koeppe R.A., Chervin R.D., Frey K.A., et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 2012, 71(4):560-568.
    • (2012) Ann. Neurol. , vol.71 , Issue.4 , pp. 560-568
    • Kotagal, V.1    Albin, R.L.2    Muller, M.L.3    Koeppe, R.A.4    Chervin, R.D.5    Frey, K.A.6
  • 12
    • 84927973245 scopus 로고    scopus 로고
    • Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET
    • Gjerløff T., Fedorova T., Knudsen K., Munk O.L., Nahimi A., Jacobsen S., et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain 2015, 138(Pt 3):653-663.
    • (2015) Brain , vol.138 , pp. 653-663
    • Gjerløff, T.1    Fedorova, T.2    Knudsen, K.3    Munk, O.L.4    Nahimi, A.5    Jacobsen, S.6
  • 13
    • 84871945993 scopus 로고    scopus 로고
    • Metabolic brain networks in translational neurology: concepts and applications
    • Niethammer M., Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann. Neurol. 2012, 72(5):635-647.
    • (2012) Ann. Neurol. , vol.72 , Issue.5 , pp. 635-647
    • Niethammer, M.1    Eidelberg, D.2
  • 14
    • 84907016741 scopus 로고    scopus 로고
    • Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers
    • Shah M., Seibyl J., Cartier A., Bhatt R., Catafau A.M. Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers. J. Nucl. Med. 2014 Sep, 55(9):1397-1400.
    • (2014) J. Nucl. Med. , vol.55 , Issue.9 , pp. 1397-1400
    • Shah, M.1    Seibyl, J.2    Cartier, A.3    Bhatt, R.4    Catafau, A.M.5
  • 15
    • 84873564460 scopus 로고    scopus 로고
    • Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent
    • Bagchi D.P., Yu L., Perlmutter J.S., Xu J., Mach R.H., Tu Z., et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One 2013, 8(2):e55031.
    • (2013) PLoS One , vol.8 , Issue.2 , pp. e55031
    • Bagchi, D.P.1    Yu, L.2    Perlmutter, J.S.3    Xu, J.4    Mach, R.H.5    Tu, Z.6
  • 16
  • 18
    • 84896840327 scopus 로고    scopus 로고
    • The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia
    • Compta Y., Parkkinen L., Kempster P., Selikhova M., Lashley T., Holton J.L., et al. The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener. Dis. 2014, 13(2-3):154-156.
    • (2014) Neurodegener. Dis. , vol.13 , Issue.2-3 , pp. 154-156
    • Compta, Y.1    Parkkinen, L.2    Kempster, P.3    Selikhova, M.4    Lashley, T.5    Holton, J.L.6
  • 19
    • 62549133546 scopus 로고    scopus 로고
    • Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    • Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8(4):382-397.
    • (2009) Lancet Neurol. , vol.8 , Issue.4 , pp. 382-397
    • Hirsch, E.C.1    Hunot, S.2
  • 20
    • 13144258735 scopus 로고    scopus 로고
    • Microglial activation and dopamine terminal loss in early Parkinson's disease
    • Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 2005, 57(2):168-175.
    • (2005) Ann. Neurol. , vol.57 , Issue.2 , pp. 168-175
    • Ouchi, Y.1    Yoshikawa, E.2    Sekine, Y.3    Futatsubashi, M.4    Kanno, T.5    Ogusu, T.6
  • 21
    • 30744472146 scopus 로고    scopus 로고
    • In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
    • Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 2006, 21(2):404-412.
    • (2006) Neurobiol. Dis. , vol.21 , Issue.2 , pp. 404-412
    • Gerhard, A.1    Pavese, N.2    Hotton, G.3    Turkheimer, F.4    Es, M.5    Hammers, A.6
  • 22
    • 28544434193 scopus 로고    scopus 로고
    • PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation
    • Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128(Pt 12):2777-2785.
    • (2005) Brain , vol.128 , pp. 2777-2785
    • Adams, J.R.1    van Netten, H.2    Schulzer, M.3    Mak, E.4    McKenzie, J.5    Strongosky, A.6
  • 23
    • 38949140887 scopus 로고    scopus 로고
    • Positron emission tomography in premotor Parkinson's disease
    • Stoessl A.J. Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13(Suppl 3):S421-S424.
    • (2007) Parkinsonism Relat. Disord. , vol.13 , pp. S421-S424
    • Stoessl, A.J.1
  • 25
    • 70350678559 scopus 로고    scopus 로고
    • Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study
    • Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C.S., et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132(Pt 11):2970-2979.
    • (2009) Brain , vol.132 , pp. 2970-2979
    • Nandhagopal, R.1    Kuramoto, L.2    Schulzer, M.3    Mak, E.4    Cragg, J.5    Lee, C.S.6
  • 27
    • 84920771791 scopus 로고    scopus 로고
    • Central pharmacokinetics of levodopa: lessons from imaging studies
    • Stoessl A.J. Central pharmacokinetics of levodopa: lessons from imaging studies. Mov. Disord. 2015, 30(1):73-79.
    • (2015) Mov. Disord. , vol.30 , Issue.1 , pp. 73-79
    • Stoessl, A.J.1
  • 28
    • 84896751626 scopus 로고    scopus 로고
    • Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients
    • Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Turkheimer F.E., et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J. Clin. Invest. 2014, 124(3):1340-1349.
    • (2014) J. Clin. Invest. , vol.124 , Issue.3 , pp. 1340-1349
    • Politis, M.1    Wu, K.2    Loane, C.3    Brooks, D.J.4    Kiferle, L.5    Turkheimer, F.E.6
  • 29
    • 79953647380 scopus 로고    scopus 로고
    • Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
    • Ahmed I., Bose S.K., Pavese N., Ramlackhansingh A., Turkheimer F., Hotton G., et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011, 134(Pt 4):979-986.
    • (2011) Brain , vol.134 , pp. 979-986
    • Ahmed, I.1    Bose, S.K.2    Pavese, N.3    Ramlackhansingh, A.4    Turkheimer, F.5    Hotton, G.6
  • 30
    • 79958163183 scopus 로고    scopus 로고
    • Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
    • Ramlackhansingh A.F., Bose S.K., Ahmed I., Turkheimer F.E., Pavese N., Brooks D.J. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 2011, 76(21):1811-1816.
    • (2011) Neurology , vol.76 , Issue.21 , pp. 1811-1816
    • Ramlackhansingh, A.F.1    Bose, S.K.2    Ahmed, I.3    Turkheimer, F.E.4    Pavese, N.5    Brooks, D.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.